Exelixis, Inc. (NASDAQ:EXEL) Shares Sold by Securian Asset Management Inc.

Securian Asset Management Inc. cut its stake in Exelixis, Inc. (NASDAQ:EXEL) by 2.7% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 26,243 shares of the biotechnology company’s stock after selling 723 shares during the period. Securian Asset Management Inc.’s holdings in Exelixis were worth $630,000 at the end of the most recent reporting period.

Other institutional investors have also recently added to or reduced their stakes in the company. Quadrant Capital Group LLC increased its stake in Exelixis by 10.8% during the fourth quarter. Quadrant Capital Group LLC now owns 7,709 shares of the biotechnology company’s stock valued at $185,000 after purchasing an additional 750 shares during the last quarter. Vanguard Personalized Indexing Management LLC increased its stake in Exelixis by 10.3% during the fourth quarter. Vanguard Personalized Indexing Management LLC now owns 39,737 shares of the biotechnology company’s stock valued at $953,000 after purchasing an additional 3,699 shares during the last quarter. USA Financial Formulas increased its stake in Exelixis by 1,548.0% during the fourth quarter. USA Financial Formulas now owns 2,060 shares of the biotechnology company’s stock valued at $49,000 after purchasing an additional 1,935 shares during the last quarter. BNP Paribas Financial Markets increased its stake in Exelixis by 88.7% during the fourth quarter. BNP Paribas Financial Markets now owns 450,097 shares of the biotechnology company’s stock valued at $10,798,000 after purchasing an additional 211,555 shares during the last quarter. Finally, E Fund Management Co. Ltd. increased its stake in Exelixis by 5.6% during the fourth quarter. E Fund Management Co. Ltd. now owns 21,832 shares of the biotechnology company’s stock valued at $524,000 after purchasing an additional 1,150 shares during the last quarter. 85.27% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other news, Director George Poste sold 11,686 shares of the company’s stock in a transaction dated Tuesday, May 21st. The stock was sold at an average price of $20.96, for a total value of $244,938.56. Following the transaction, the director now owns 213,907 shares in the company, valued at approximately $4,483,490.72. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In other news, Director George Poste sold 11,686 shares of the company’s stock in a transaction dated Tuesday, May 21st. The stock was sold at an average price of $20.96, for a total value of $244,938.56. Following the transaction, the director now owns 213,907 shares in the company, valued at approximately $4,483,490.72. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Patrick J. Haley sold 47,020 shares of the company’s stock in a transaction dated Friday, February 23rd. The shares were sold at an average price of $21.45, for a total value of $1,008,579.00. Following the completion of the transaction, the executive vice president now owns 384,866 shares in the company, valued at approximately $8,255,375.70. The disclosure for this sale can be found here. Insiders have sold 88,834 shares of company stock worth $1,948,054 in the last 90 days. Company insiders own 2.85% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have weighed in on EXEL. TD Cowen boosted their target price on shares of Exelixis from $25.00 to $27.00 and gave the company a “buy” rating in a research note on Wednesday, May 1st. William Blair restated an “outperform” rating on shares of Exelixis in a research report on Wednesday, May 1st. Barclays lowered shares of Exelixis from an “overweight” rating to an “equal weight” rating and set a $25.00 price target for the company. in a research report on Thursday, April 11th. HC Wainwright restated a “buy” rating and set a $28.00 price target on shares of Exelixis in a research report on Friday, May 3rd. Finally, Stifel Nicolaus upped their price target on shares of Exelixis from $23.00 to $25.00 and gave the stock a “hold” rating in a research report on Friday, February 2nd. Seven equities research analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $26.13.

Exelixis Trading Down 0.1 %

EXEL stock opened at $21.00 on Thursday. Exelixis, Inc. has a one year low of $18.64 and a one year high of $24.34. The firm has a market capitalization of $6.37 billion, a PE ratio of 32.81, a P/E/G ratio of 0.51 and a beta of 0.57. The firm has a 50-day moving average of $22.74 and a two-hundred day moving average of $22.30.

Exelixis (NASDAQ:EXEL) last posted its quarterly earnings data on Tuesday, April 30th. The biotechnology company reported $0.12 EPS for the quarter, missing analysts’ consensus estimates of $0.28 by ($0.16). Exelixis had a net margin of 11.10% and a return on equity of 8.85%. The firm had revenue of $425.23 million for the quarter, compared to analysts’ expectations of $461.04 million. During the same period in the prior year, the company posted $0.12 earnings per share. Exelixis’s quarterly revenue was up 4.0% compared to the same quarter last year. On average, equities research analysts anticipate that Exelixis, Inc. will post 1.16 earnings per share for the current year.

Exelixis Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.